Xencor Inc XNCR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if XNCR is a good fit for your portfolio.
News
-
Xencor Appoints Bart Cornelissen as Chief Financial Officer
-
Xencor to Present at Upcoming Investor Conferences
-
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
-
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
Trading Information
- Previous Close Price
- $19.23
- Day Range
- $19.14–20.41
- 52-Week Range
- $16.49–28.96
- Bid/Ask
- $19.95 / $19.99
- Market Cap
- $1.23 Bil
- Volume/Avg
- 375,500 / 701,512
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.18
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 280
- Website
- https://www.xencor.com
Comparables
Valuation
|
Metric
|
XNCR
|
CLDX
|
CELC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.82 | 4.73 | 2.91 |
Price/Sales | 7.18 | 255.51 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
XNCR
CLDX
CELC
Financial Strength
|
Metric
|
XNCR
|
CLDX
|
CELC
|
|---|---|---|---|
Quick Ratio | 7.14 | 13.69 | 12.78 |
Current Ratio | 7.36 | 13.87 | 13.43 |
Interest Coverage | — | — | −12.43 |
Quick Ratio
XNCR
CLDX
CELC
Profitability
|
Metric
|
XNCR
|
CLDX
|
CELC
|
|---|---|---|---|
Return on Assets (Normalized) | −9.75% | −30.49% | −35.57% |
Return on Equity (Normalized) | −11.83% | −33.19% | −49.08% |
Return on Invested Capital (Normalized) | −12.77% | −32.85% | −39.21% |
Return on Assets
XNCR
CLDX
CELC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fzszxnpfs | Xvysd | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Csyryyqb | Xwtdpr | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fbzmtpbz | Fkbsq | $97.8 Bil | |
MRNA
| Moderna Inc | Kzzwhfgw | Rthyh | $41.3 Bil | |
ARGX
| argenx SE ADR | Gflgcvhrj | Kdhd | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Bwzphtmp | Jhs | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lqmbztyd | Qhxlhcs | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hsdyvjn | Srvrn | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qjknmnlggt | Vrfvy | $12.5 Bil | |
INCY
| Incyte Corp | Zchgpyzfx | Grvfp | $11.6 Bil |